Big Pharma Split (TSX:PRM) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)


TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split LT-Debt-to-Total-Asset?

Big Pharma Split TSX:PRM 7 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Big Pharma Split's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Big Pharma Split's long-term debt to total assets ratio stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Big Pharma Split  (TSX:PRM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Big Pharma Split LT-Debt-to-Total-Asset Related Terms

Big Pharma Split LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Big Pharma Split's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Big Pharma Split LT-Debt-to-Total-Asset Chart

Big Pharma Split Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Big Pharma Split Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split LT-Debt-to-Total-Asset Calculation

Big Pharma Split's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/31.841
=0.00

Big Pharma Split's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0/31.841
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Big Pharma Split (TSX:PRM) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's LT-Debt-to-Total-Asset too high?
Big Pharma Split's current LT-Debt-to-Total-Asset is 0.00. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's LT-Debt-to-Total-Asset compare to BLK and BX?
Big Pharma Split's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for an Asset Management company?
A good LT-Debt-to-Total-Asset depends on the Asset Management industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Big Pharma Split and its competitors. Big Pharma Split's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value